Overview
Sermorelin is a synthetic analog representing residues 1-29 of human growth hormone-releasing hormone (GHRH), identified as the minimum sequence retaining full biological activity of the native hormone. Unlike the GHRP-class secretagogues that act at the ghrelin receptor, sermorelin works through the GHRH receptor pathway.
Historically it has been studied in research and clinical settings as a diagnostic agent for pituitary function and in investigations of growth hormone insufficiency, making it one of the better-characterized peptides in this category.
Mechanism of action
Research describes sermorelin as an agonist of the GHRH receptor on pituitary somatotrophs. Receptor activation is associated with increased intracellular cyclic AMP and the synthesis and release of growth hormone, mirroring the action of endogenous GHRH.
Because it operates through the native GHRH pathway, study literature notes that its effect is subject to physiological feedback, including modulation by somatostatin tone, which preserves a degree of pulsatile regulation in experimental models.
Research findings
Studied as the shortest fully active fragment of human GHRH.,Investigated historically as a diagnostic probe of pituitary growth hormone reserve.,Research suggests growth hormone release subject to physiological feedback regulation.,Examined in pediatric growth research in earlier clinical literature.,Studied alongside ghrelin-receptor secretagogues for combined effects.
Research context
Pharmacokinetic research reports a notably short plasma half-life for sermorelin, generally on the order of ten to twenty minutes, reflecting rapid enzymatic degradation of the GHRH(1-29) sequence. Study designs and measured parameters vary by population and assay, and the peptide’s action remains coupled to endogenous feedback systems. This is a research reference only. Not approved for human use outside regulated settings; consult the primary literature.
Handling & storage
Commonly described in laboratory use as a lyophilized powder stored desiccated and protected from light. Long-term storage is generally reported at -20°C or below, with reconstituted solutions refrigerated for short periods. Handle using standard laboratory practices for peptide research chemicals.
Reported safety signals
Research and historical clinical literature note possible transient effects such as flushing, headache, and injection-site reactions in study contexts. Because it acts through the native GHRH pathway, some reports describe a more physiologic profile than direct secretagogues, though data remain limited.
Studied alongside
Sermorelin has been studied alongside ghrelin-receptor secretagogues such as GHRP-2, GHRP-6, and ipamorelin, where GHRH-pathway and GHS-pathway activity have been examined in combination in research designs.
At a glance
Research strengths
- Acts through the native GHRH receptor pathway
- Growth hormone release retains physiological feedback in models
- Comparatively well-characterized historical research base
- Studied in combination with ghrelin-receptor secretagogues
Limitations & cautions
- Very short reported half-life from rapid degradation
- Effect dependent on intact pituitary somatotroph function
- Possible flushing and headache reported in research
- Not approved for general human therapeutic use as a research chemical
